NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Krystal Biotech, Inc. Common Stock (KRYS) Stock Analysis

Krystal Biotech, Inc. Common Stock (KRYS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KRYS

$358.24

−$13.23 (−3.56%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KRYS with… →

KRYS Key Statistics

As of Sep 4, 2026
Trading
Open
$365.45
Previous Close
$371.47
Day's Range
353.75–371.99
52-Week Range
136.73–382.54
Volume
323.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.54
Valuation
Market Cap
$10.60B
P/E Ratio
44.84
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
38.12
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
24.07
EPS (ttm)Profit attributable to each share over the last twelve months.
7.99
Financials (FY)
Revenue (FY)
$389.13M+33.94%
Net Income (FY)
$204.83M+129.74%
Profit marginThe share of revenue left as profit after all costs and taxes.
54.82%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
29.60M
1-Year Return
+139.23%
Dividend and dates
Earnings Date
November 2, 2026estimated
Avg Volume
412.03K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KRYS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+45.31%
2025+57.37%
2024+26.28%
2023+56.60%
2022+13.25%
2021+16.58%
2020+8.34%
2019+166.51%
2018+97.53%
2017 (partial year)−1.13%

As of September 4, 2026.

KRYS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$389.13M$204.83M52.6%
2024$290.52M$89.16M30.7%
2023$50.70M$10.93M21.6%
2022$0.00−$139.98M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$389.13M$366.08M$161.30M$204.83M52.6%
2024$290.52M$270.45M$103.25M$89.16M30.7%
2023$50.70M$47.61M−$97.12M$10.93M21.6%
2022$0.00$0.00−$120.20M−$139.98M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KRYS Valuation vs Biotechnology Median

Median of 656 stocks
MetricKRYSBiotechnology medianvs median
P/E44.8412.573.6x the median
P/S ratio24.0715.2658% above
Profit margin54.82%0.00%54.8 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Krystal Biotech, Inc. Common Stock (KRYS) carries a market capitalisation of $10.60B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 295.

Over the past 52 weeks the price has ranged from $136.73 to $382.54. KRYS last closed at $358.24 on September 4, 2026. That is −$13.23 (−3.56%) against the previous close. The latest close sits 162.01% above that 52-week low.

Financial Health

In fiscal 2025, Krystal Biotech, Inc. Common Stock reported revenue of $389.13M. That is +33.94% against the prior fiscal year, when revenue was $290.52M. Net income for the same year was $204.83M. That is +129.74% against the prior fiscal year. Profit margin runs at 54.82%. That is 54.8 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 7.99.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $389.13M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 44.84 times earnings. That is 3.6 times the Biotechnology median of 12.57. On forward earnings the ratio is 38.12. The price-to-sales ratio is 24.07. On price-to-sales that is 57.71% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +139.23%. Measured over 5 years, that is +43.65% a year compounded. The reported beta is 0.54. Daily returns over the trailing 9 years annualize to a volatility of 73.51%.

Growth & Income

The record shows no dividend for KRYS.

2026 is still running; the price is +45.31% year to date. Across the complete calendar years on file, 2019 returned +166.51% and 2020 returned +8.34%. Of the 8 complete calendar years on file, 8 finished higher.

Peer Comparison

Krystal Biotech, Inc. Common Stock (KRYS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Krystal Biotech, Inc. Common Stock KRYS $10.60B 44.8
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Krystal Biotech, Inc. Common Stock trades at a P/E of 44.8.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Krystal Biotech, Inc. Common Stock

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Visit website →